Panagene Inc (046210) Fair Value & Analysis
Healthcare · KR · Market cap 66.1B KRW
Fair value as of: Jun 24, 2026
Analysis
Panagene Inc (046210) currently trades at 1,432 KRW, while our model-based Fair Value estimate is 10,131 KRW — implying the stock looks roughly 607.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The company was formerly known as Koram Panagene Ltd. and changed its name to Panagene Inc. in January 2009. Panagene Inc. was incorporated in 1976 and is based in Daejeon, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Panagene Inc (046210) undervalued?
What is the fair value of 046210?
What is the quality score of 046210?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.